Skip to main content
. Author manuscript; available in PMC: 2020 May 15.
Published in final edited form as: Am J Cardiol. 2019 Feb 23;123(10):1660–1666. doi: 10.1016/j.amjcard.2019.02.025

Figure 2.

Figure 2

(A-E). Levels of physical activity, natriuretic peptides, and quality of life scores after maximally tolerated doses of isosorbide mononitrate and placebo and their treatment difference by AF/AFL status. Bars signify median and interquartile range. P-values represent interaction by AF/AFL status of change in endpoints from baseline after isosorbide mononitrate. 6MWD = 6-minute walk distance; AF/AFL: atrial fibrillation and/or atrial flutter; KCCQ= Kansas City Cardiomyopathy Questionnaire; NT-proBNP= N-terminal pro-B-type natriuretic peptide.